Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
To determine whether the presenilin 1 (PS1), presenilin 2 (PS2) and amyloid beta-protein precursor (APP) mutations linked to familial Alzheimer's disease (FAD) increase the extracellular concentration of amyloid beta-protein (A beta) ending at A beta 42(43) in vivo, we performed a blinded comparison of plasma A beta levels in carriers of these mutations and controls. A beta 1-42(43) was elevated in plasma from subjects with FAD-linked PS1 (P < 0.0001), PS2N1411 (P = 0.009), APPK670N,M671L (P < 0.0001), and APPV7171 (one subject) mutations. A beta ending at A beta 42(43) was also significantly elevated in fibroblast media from subjects with PS1 (P < 0.0001) or PS2 (P = 0.03) mutations. These findings indicate that the FAD-linked mutations may all cause Alzhelmer's disease by increasing the extracellular concentration of A beta 42(43), thereby fostering cerebral deposition of this highly amyloidogenic peptide.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aβ is produced by sequential β- and γ-secretase proteolytic cleavage of the amyloid precursor protein (APP) [11–17].”
From Amyloid-β interrupts canonical Sonic hedgehog signaling by distorting primary cilia structure (2018) · cites this paper as [11]
In the citing paper
“Similar to PSEN1 , PSEN2 mutations may also cause increased production of long A 𝛃 peptide species (481, 523), although this needs more investigation.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [523]
In the citing paper
“It is well established that this mutation causes concomitant increases in secreted A42 and A40 (Cai et al., 1993;Citron et al., 1994;Scheuner et al., 1996).”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
In the citing paper
“In a previous study of human plasma (Scheuner et al., 1996), we showed that the Swedish APP K670N,M671L mutation increases both A42 and A40 and that other FAD-linked APP, PS1, and PS2 mutations selectively increase A42.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
In the citing paper
“In that report, we suggested that cerebral A deposition in FAD occurs because of an increase in CNS A that develops as part of a generalized genetic effect that also increases plasma A.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationCloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Self-citationCandidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Self-citationJarrett, J. T., & Lansbury, P. T. (1993) · Cell · doi:10.1016/0092-8674(93)90635-4 · Cited by 2,178
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Self-citationJarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Self-citationCitron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
Self-citationIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Self-citation
Cited by
Items 801–900 of 2,576
Das, R. C., Rauf, A., Akhter, S., Islam, M. N., Emran, T. B., Mitra, S., Khan, I. N., & Mubarak, M. S. (2021) · Molecules · doi:10.3390/molecules26123696 · Cited by 83
“Although soluble, Aβ40 is substantially more prevalent than soluble Aβ42; Aβ42 has a greater tendency for aggregation because of the hydrophobicity within its two terminal residues.”
BackgroundInfluentialEtiology and Pathogenesis of Late-Onset Alzheimer’s Disease
Balin, B. J., & Hudson, A. P. (2014) · Current Allergy and Asthma Reports · doi:10.1007/s11882-013-0417-1 · Cited by 101
Blood-based biomarkers for Alzheimer's disease: plasma Aβ40 and Aβ42, and genetic variants
Mayeux, R., & Schupf, N. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.09.004 · Cited by 79
Gylys, K. H., Fein, J. A., Tan, A. M., & Cole, G. M. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01643.x · Cited by 70
“The longer, more fibrillogenic 1–42 peptide is more abundant in Alzheimer’s disease (AD) brain than in controls (Roher et al. 1993), and presenilin mutations that result in early onset AD increase production of 1–42 peptide (Scheuner et al. 1996).”
BackgroundGuix, F. X., Wahle, T., Vennekens, K., Snellinx, A., Chávez‐Gutiérrez, L., Ill‐Raga, G., Ramos‐Fernandez, E., Guardia‐Laguarta, C., Lleó, A., Arimon, M., et al. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201200243 · Cited by 78
“Interestingly FAD mutations lead to an altered processing of APP and an increase in the Ab42/Ab40 ratio (Scheuner et al, 1996).”
BackgroundResultE3 Ubiquitin Ligases Neurobiological Mechanisms: Development to Degeneration
Upadhyay, A., Joshi, V., Amanullah, A., Mishra, R., Arora, N., Prasad, A., & Mishra, A. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00151 · Cited by 87
“…of these, Alzheimer’s disease, has been reported to be caused due to mutations in genes, like APP (Goate and Chartier-Harlin, 1991), presenilins (Scheuner et al., 1996), tau (Hutton et al., 1998), etc. Apolipoprotein E (ApoE), in recent years, have also been shown as one of the risk factors…”
BackgroundMuscarinic m1 receptor agonists increase the secretion of the amyloid precursor protein ectodomain
Müller, D., Mendla, K. D., Farber, S. A., & Nitsch, R. M. (1997) · Life Sciences · doi:10.1016/s0024-3205(97)00038-6 · Cited by 84
Shioi, J., Georgakopoulos, A., Mehta, P., Kouchi, Z., Litterst, C. M., Baki, L., & Robakis, N. K. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04391.x · Cited by 79
“…674–681 neurotoxic Ab 42, reported increases were variable and in several cell culture studies, FAD mutants failed to significantly increase secreted Ab 42 or the Ab 42/40 ratio [(Scheuner et al. 1996; Murayama et al. 1999a; Walker et al. 2005; Bentahir et al. 2006), Takashima et al. pers. comm.].”
BackgroundInfluentialHole, K. L., & Williams, R. J. (2020) · Brain Plasticity · doi:10.3233/bpl-200098 · Cited by 82
Santiago, J. A., & Potashkin, J. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083940 · Cited by 81
Alzheimer dementia caused by a novel mutation located in the APP C-terminal intracytosolic fragment
Theuns, J., Marjaux, E., Vandenbulcke, M., Van Laere, K., Kumar-Singh, S., Bormans, G., Brouwers, N., Van den Broeck, M., Vennekens, K., Corsmit, E., et al. (2006) · Human Mutation · doi:10.1002/humu.20402 · Cited by 79
“The majority of early-onset AD mutations alter processing of APP in such a way that the relative level of the 42 aa isoform of the Ab (Ab42) peptide is increased, either by increasing Ab42 or decreasing Ab40 peptide levels or both [Scheuner et al., 1996; Walker et al., 2005].”
Change in plasma Aβ peptides and onset of dementia in adults with Down syndrome
Schupf, N., Zigman, W. B., Tang, M.-X., Pang, D., Mayeux, R., Mehta, P., & Silverman, W. (2010) · Neurology · doi:10.1212/wnl.0b013e3181fb448b · Cited by 79
Changes in the ageing brain in health and disease
Anderton, B. H. (1997) · Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences · doi:10.1098/rstb.1997.0162 · Cited by 77
“…compared to Ab40, as do cells transfected with mutant presenilins, and plasma from Alzheimer's patients possessing mutant presenilins also has relatively more Ab42 as do the brains from transgenic mice expressing such mutant presenilins (Scheuner et al. 1996; Du¡ et al. 1996; Borchelt et al. 1996).”
Backgroundβ-Peptide Immunization: A Possible New Treatment for Alzheimer Disease
Schenk, D. B., Seubert, P., Lieberburg, I., & Wallace, J. (2000) · Archives of Neurology · doi:10.1001/archneur.57.7.934 · Cited by 77
Curcuminoids and resveratrol as anti-Alzheimer agents
Villaflores, O. B., Chen, Y.-J., Chen, C.-P., Yeh, J.-M., & Wu, T.-Y. (2012) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2012.09.005 · Cited by 77
TRPC Channels and their Implications for Neurological Diseases
Selvaraj, S., Sun, Y., & Singh, B. B. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710790966650 · Cited by 83
The amyloid precursor protein of Alzheimer disease in human brain and blood
Li, Q.-X., Fuller, S. J., Beyreuther, K., & Masters, C. L. (1999) · Journal of Leukocyte Biology · doi:10.1002/jlb.66.4.567 · Cited by 77
Pramanik, S., Sulistio, Y. A., & Heese, K. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0214-7 · Cited by 82
Rat transgenic models with a phenotype of intracellular Aβ accumulation in hippocampus and cortex
Echeverria, V., Ducatenzeiler, A., Alhonen, L., Janne, J., Grant, S. M., Wandosell, F., Muro, A., Baralle, F., Li, H., Duff, K., et al. (2004) · Journal of Alzheimer's Disease · doi:10.3233/jad-2004-6301 · Cited by 77
hFE65L Influences Amyloid Precursor Protein Maturation and Secretion
Guénette, S. Y., Chen, J., Ferland, A., Haass, C., Capell, A., & Tanzi, R. E. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0730985.x · Cited by 78
“However, enhanced Ab production is clearly associated with familial AD mutations in APP and the presenilin genes (Citron et al., 1992; Cai et al., 1993; Suzuki et al., 1994; Scheuner et al., 1996).”
BackgroundSelf-citationFunction and Dysfunction of the Presenilins
Sisodia, S. S., Kim, S. H., & Thinakaran, G. (1999) · The American Journal of Human Genetics · doi:10.1086/302475 · Cited by 76
Complement System in Alzheimer’s Disease
Shah, A., Kishore, U., & Shastri, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413647 · Cited by 73
“P3 is a soluble peptide which does not tend to aggregate unlike Aβ [21].”
BackgroundInfluentialMckean, N. E., Handley, R. R., & Snell, R. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313168 · Cited by 88
Platelet β-secretase activity is increased in Alzheimer's disease
Johnston, J. A., Liu, W. W., Coulson, D. T. R., Todd, S., Murphy, S., Brennan, S., Foy, C. J., Craig, D., Irvine, G. B., & Passmore, A. P. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.11.003 · Cited by 84
Blocking ADAM10 synaptic trafficking generates a model of sporadic Alzheimer’s disease
Epis, R., Marcello, E. E., Gardoni, F., Vastagh, C., Malinverno, M., Balducci, C., Colombo, A. V., Borroni, B., Vara, H., Dell’Agli, M., et al. (2010) · Brain · doi:10.1093/brain/awq217 · Cited by 93
“Identification in various human pedigrees of gene mutations in amyloid precursor protein (Goate et al., 1991), in presenilin-1 and -2 (Scheuner et al., 1996) provided a potential tool of generating rodent models of the disease.”
Backgroundβ-Amyloid Protein Structure Determines the Nature of Cytokine Release From Rat Microglia
Lindberg, C., Selenica, M. B., Westlind‐Danielsson, A., & Schultzberg, M. (2005) · Journal of Molecular Neuroscience · doi:10.1385/jmn:27:1:001 · Cited by 83
“Aβ1–40 has a significantly lower aggregation potential than Aβ1–42 (Jarrett et al., 1993) and is the dominating form of Aβ found in plasma and CSF from AD patients (Vigo-Pelfrey et al., 1993; Scheuner et al., 1996).”
BackgroundFunctional Phenotype in Transgenic Mice Expressing Mutant Human Presenilin-1
Barrow, P. A., Empson, R. M., Gladwell, S. J., Anderson, C. M., Killick, R., Yu, X., Jefferys, J. G. R., & Duff, K. (2000) · Neurobiology of Disease · doi:10.1006/nbdi.1999.0276 · Cited by 74
“An increased ratio of Ab42(43) relative to Ab40 was first described in fibroblasts from AD patients with PS1 mutations (Scheuner et al., 1996) and was subsequently confirmed in transfected cells and transgenic mice that overexpress mutant (but not wild-type) PS1.”
BackgroundExpression and activity of β-site amyloid precursor protein cleaving enzyme in Alzheimer's disease
Liu, W. W., Johnston, J. A., Todd, S. A., Coulson, D. T. R., Murphy, S., Irvine, G. B., & Passmore, A. P. (2005) · Biochemical Society Transactions · doi:10.1042/bst20051096 · Cited by 71
Mattson, M. P., Goodman, Y., Luo, H., Fu, W., & Furukawa, K. (1997) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19970915)49:6<681::aid-jnr3>3.0.co;2-3 · Cited by 567
Peripheral Biomarkers of Alzheimer's Disease
Khan, T. K., & Alkon, D. L. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-142262 · Cited by 75
“For example, primary human skin fibroblasts of symptomatic and presymptomatic patients carrying the Swedish familial AD mutation produce excess A protein [10–13].”
BackgroundLeal, N. S., Dentoni, G., Schreiner, B., Naia, L., Piras, A., Graff, C., Cattaneo, A., Meli, G., Hamasaki, M., Nilsson, P., et al. (2020) · Cells · doi:10.3390/cells9122552 · Cited by 73
Yu, W., Jin, H., & Huang, Y. (2021) · Clinical Science · doi:10.1042/cs20200844 · Cited by 81
“Significant mutations in APP or/and PSEN1/2 might lead to the excessive generation of A β 42 and the increased ratio of A β 42/40 [20].”
BackgroundChhatwal, J. P., Schultz, S. A., McDade, E., Schultz, A. P., Liu, L., Hanseeuw, B. J., Joseph-Mathurin, N., Feldman, R., Fitzpatrick, C. D., Sparks, K. P., et al. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00375-6 · Cited by 72
Comparison of Aβ levels in the brain of familial and sporadic Alzheimer's disease
Hellström-Lindahl, E., Viitanen, M., & Marutle, A. (2009) · Neurochemistry International · doi:10.1016/j.neuint.2009.03.007 · Cited by 74
Self-citationWhalen, B. M., Selkoe, D. J., & Hartley, D. M. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.03.007 · Cited by 75
“…and presenilin-2 genes and in the amyloid-h protein precursor (APP) gene alter Ah production, most notably by increasing the production of the highly amyloidogenic Ah1–42 form of the peptide (Borchelt et al., 1996; Citron et al., 1997; Duff et al., 1996; Scheuner et al., 1996; Tomita et al., 1997).”
BackgroundSelf-citationCacquevel, M., Aeschbach, L., Houacine, J., & Fraering, P. C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035133 · Cited by 75
“specie deposited in the brain of AD patients [16,39], is more prone to aggregation when compared to shorter Ab species [40,41,42], it has been implicated in the seeding of amyloid plaques in AD patients with PSEN1 mutations [43].”
Backgroundβ-Amyloid Production, Aggregation, and Clearance as Targets for Therapy in Alzheimer's Disease
Felice, F. G. D., & Ferreira, S. T. (2002) · Cellular and Molecular Neurobiology · doi:10.1023/a:1021832302524 · Cited by 91
“The correct balance between production and catabolism of Aβ appears directly related to the development of AD, as the overproduction of Aβ is not followed by a parallel increase in its clearance in familiar or sporadic forms of the disease (Hardy, 1997; Scheuner et al., 1996).”
BackgroundRusso, C., Salis, S., Dolcini, V., Venezia, V., Song, X., Teller, J. K., & Schettini, G. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0357 · Cited by 75
Self-citationA novel presenilin‐1 mutation: Increased β‐amyloid and neurofibrillary changes
Gómez‐Isla, T., Wasco, W., Pettingell, W. P., Gurubhagavatula, S., Schmidt, S. D., Jondro, P. D., McNamara, M., Rodes, L. A., Diblasi, T., Growdon, W. B., et al. (1997) · Annals of Neurology · doi:10.1002/ana.410410618 · Cited by 76
Self-citationMcPhie, D. L., Lee, R. K. K., Eckman, C. B., Olstein, D. H., Durham, S. P., Yager, D., Younkin, S. G., Wurtman, R. J., & Neve, R. L. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.40.24743 · Cited by 75
Self-citationTeunissen, C. E., Veerhuis, R., De Vente, J., Verhey, F. R. J., Vreeling, F., van Boxtel, M. P. J., Glatz, J. F. C., & Pelsers, M. A. L. (2011) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03273.x · Cited by 74
La Barbera, L., Mauri, E., D’Amelio, M., & Gori, M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.939855 · Cited by 74
“The principal genetic causes of AD are mutations in different genes, such as APP (Goate et al., 1991), γ-secretase proteins presenilin-1 and presenilin-2 (PSEN1-2) (Scheuner et al., 1996), which result in the production of aggregation-prone Aβ peptides, called oligomers.”
BackgroundDesai, M. K., Guercio, B. J., Narrow, W. C., & Bowers, W. J. (2011) · Glia · doi:10.1002/glia.21131 · Cited by 75
“PS1 is the catalytic component of the multi-subunit gamma secretase complex, arguably best known for its role in amyloidogenic processing of APP to yield pathogenic Aβ peptide species (Scheuner et al. 1996).”
BackgroundBiochemical Markers of Aging for Longitudinal Studies in Humans
Engelfriet, P. M., Jansen, E. H. J. M., Picavet, H. S. J., & Dolle, M. E. T. (2013) · Epidemiologic Reviews · doi:10.1093/epirev/mxs011 · Cited by 72
Increased amyloidogenic secretion in cerebellar granule cells undergoing apoptosis
Galli, C., Piccini, A., Ciotti, M. T., Castellani, L., Calissano, P., Zaccheo, D., & Tabaton, M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.3.1247 · Cited by 74
Implication of APP Secretases in Notch Signaling
Hartmann, D., Tournoy, J., Säftig, P., Annaert, W. G., & Strooper, B. D. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:17:2:171 · Cited by 76
“Mutations in both genes (as yet, 82 are reported for PS1, only 6 for PS2; http://molgen-www.uia.ac.be/ADmutations/) modify the γ-secretase cleavage of APP, causing the generation of a higher proportion of the less soluble Aβ1-42 as compared to the otherwise predominating Aβ1-40 (Scheuner et al., 1996; Duff et al., 199…”
BackgroundSaura, C. A., Tomita, T., Davenport, F., Harris, C. L., Iwatsubo, T., & Thinakaran, G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.20.13818 · Cited by 75
Mann, D. M. A., Davidson, Y. S., Robinson, A. C., Allen, N., Hashimoto, T., Richardson, A., Jones, M., Snowden, J. S., Pendleton, N., Potier, M.-C., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1866-3 · Cited by 73
Cathepsin D regulates cerebral Aβ42/40 ratios via differential degradation of Aβ42 and Aβ40
Suire, C. N., Abdul-Hay, S. O., Sahara, T., Kang, D., Brizuela, M. K., Saftig, P., Dickson, D. W., Rosenberry, T. L., & Leissring, M. A. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00649-8 · Cited by 73
“2c), an increase comparable in scale to that induced by many AD-linked presenilin mutations [29, 32, 33].”
Head, E., Doran, E., Nistor, M., Hill, M., Schmitt, F. A., Haier, R. J., & Lott, I. T. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-101335 · Cited by 74
Knafo, S., Venero, C., Merino‐Serrais, P., Fernaud‐Espinosa, I., Gonzalez‐Soriano, J., Ferrer, I., Santpere, G., & DeFelipe, J. (2009) · The Journal of Pathology · doi:10.1002/path.2565 · Cited by 73
“The APP/PS1 mouse line used in this study (age 12–14 months, males) expressed a Mo/Hu APP695swe construct in conjunction with the exon-9-deleted variant of human presenilin 1 (PS1-dE9) [25].”
Familial Frontotemporal Dementia Associated with a Novel Presenilin-1 Mutation
Tang-Wai, D., Lewis, P., Boeve, B., Hutton, M., Golde, T., Baker, M., Hardy, J., Michels, V., Ivnik, R., Jack, C., et al. (2002) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000058328 · Cited by 73
Self-citationIncreased sensitivity of fibroblasts from amyotrophic lateral sclerosis patients to oxidative stress
Aguirre, T., Bosch, L. V. D., Goetschalckx, K., Tilkin, P., Mathijis, G., Cassiman, J. J., & Robberecht, W. (1998) · Annals of Neurology · doi:10.1002/ana.410430407 · Cited by 73
Tysoe, C. J., Whittaker, J., Xuereb, J. H., Cairns, N. J., Cruts, M., Broeckhoven, C. V., Wilcock, G. K., & Rubinsztein, D. C. (1998) · The American Journal of Human Genetics · doi:10.1086/301672 · Cited by 82
“…lines transfected with familial presenilin mutations have increased production of the amyloidogenic 42-residue amyloid b-peptide, whereas no such effect was seen when the mice or the cell lines were transfected with the wild-type gene (Duff et al. 1996; Scheuner et al. 1996; Citron et al. 1997).”
BackgroundViles, J. H. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202215785 · Cited by 82
Dementia: Alzheimer pathology and vascular factors: From mutually exclusive to interaction
van Norden, A. G. W., van Dijk, E. J., de Laat, K. F., Scheltens, P., Olde-Rikkert, M. G. M., & de Leeuw, F. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.07.003 · Cited by 89
Human plasma semicarbazide sensitive amine oxidase (SSAO), β-amyloid protein and aging
Hernandez, M. D. M., Esteban, M., Szabo, P., Boada, M., & Unzeta, M. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.04.074 · Cited by 72
Accumulation of murine amyloidβ42 in a gene‐dosage‐dependent manner in PS1 ‘knock‐in’ mice
Nakano, Y., Kondoh, G., Kudo, T., Imaizumi, K., Kato, M., Miyazaki, J., Tohyama, M., Takeda, J., & Takeda, M. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00698.x · Cited by 70
“Recent studies indicate that conditioned medium from ®broblasts of AD patients with FAD-linked PS1/PS2 mutations contains signi®cantly more Ab42(3) than the medium from control ®broblasts (Scheuner et al., 1996).”
BackgroundEffect of Anti-inflammatory Medications on Neuropathological Findings in Alzheimer Disease
Halliday, G. M., Shepherd, C. E., McCann, H., Reid, W. G. J., Grayson, D. A., Broe, G. A., & Kril, J. J. (2000) · Archives of Neurology · doi:10.1001/archneur.57.6.831 · Cited by 72
Kawahata, I., & Fukunaga, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113779 · Cited by 71
Presenilin-1 adopts pathogenic conformation in normal aging and in sporadic Alzheimer’s disease
Wahlster, L., Arimon, M., Nasser-Ghodsi, N., Post, K. L., Serrano-Pozo, A., Uemura, K., & Berezovska, O. (2013) · Acta Neuropathologica · doi:10.1007/s00401-012-1065-6 · Cited by 71
Ryan, D. A., Mastrangelo, M. A., Narrow, W. C., Sullivan, M. A., Federoff, H. J., & Bowers, W. J. (2010) · Molecular Therapy · doi:10.1038/mt.2010.111 · Cited by 72
Genetic risk factors in Alzheimer's disease.
Tilley, L. A., Morgan, K., & Kalsheker, N. A. (1998) · Molecular Pathology · doi:10.1136/mp.51.6.293 · Cited by 92
Mechanisms of AD neurodegeneration may be independent of Aβ and its derivatives
Robakis, N. K. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.022 · Cited by 72
“…role of A in AD is derived from reports that FAD mutations of PS invariably increase production of neurotoxic A 42 by causng a gain of -secretase function, the activity involved in he production of this peptide (Borchelt et al., 1996; Citron t al., 1997; Klein et al., 2001; Scheuner et al., 1996).”
BackgroundA Brief History of Alzheimer's Disease Gene Discovery
Tanzi, R. E. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-129044 · Cited by 71
“Most of the EO-FAD mutations are in PSEN1 and the majority of them, in all three of the genes, lead to an increase in the ratio of A 42 : A 40 [7, 25].”
Self-citationLi, G., Faibushevich, A., Turunen, B. J., Yoon, S. O., Georg, G., Michaelis, M. L., & Dobrowsky, R. T. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01526.x · Cited by 71
“…and parkinsonism linked to chromosome 17 (FTDP-17) has provided strong evidence that tau abnormalities are sufficient to promote neurodegeneration (Scheuner et al. 1996; Goedert et al. 1998; Spillantini et al. 1998)., Abnormal phosphorylation of tau by Ab peptides promotes the loss of its…”
BackgroundPresenilin 1 Protein Directly Interacts with Bcl-2
Alberici, A., Moratto, D., Benussi, L., Gasparini, L., Ghidoni, R., Gatta, L. B., Finazzi, D., Frisoni, G. B., Trabucchi, M., Growdon, J. H., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.43.30764 · Cited by 80
Mutations in APP have independent effects on Aβ and CTFγ generation
Hecimovic, S., Wang, J., Dolios, G., Martinez, M., Wang, R., & Goate, A. M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.04.018 · Cited by 70
Llano, D. A., Devanarayan, V., & Simon, A. J. (2013) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31826d597a · Cited by 69
Validating GWAS-Identified Risk Loci for Alzheimer’s Disease in Han Chinese Populations
Wang, H.-Z., Bi, R., Hu, Q.-X., Xiang, Q., Zhang, C., Zhang, D., Zhang, W., Ma, X., Guo, W., Deng, W., et al. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-9015-z · Cited by 74
Neuronal Ryanodine Receptors in Development and Aging
Abu-Omar, N., Das, J., Szeto, V., & Feng, Z. (2017) · Molecular Neurobiology · doi:10.1007/s12035-016-0375-4 · Cited by 85
Celecoxib Prevents Cognitive Impairment and Neuroinflammation in Soluble Amyloid β-treated Rats
Mhillaj, E., Morgese, M. G., Tucci, P., Furiano, A., Luongo, L., Bové, M., Maione, S., Cuomo, V., Schiavone, S., & Trabace, L. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2017.12.046 · Cited by 78
Nitric oxide in the cerebral cortex of amyloid-precursor protein (SW) Tg2576 transgenic mice
Rodrigo, J., Fernández‐Vizarra, P., Castro‐Blanco, S., Bentura, M. L., Nieto, M., Gómez‐Isla, T., Martínez‐Murillo, R., Martínez, A., Serrano, J., & Fernández, A. P. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.06.030 · Cited by 77
Quantification of Alzheimer Amyloid β Peptides Ending at Residues 40 and 42 by Novel ELISA Systems
Jensen, M., Hartmann, T., Engvall, B., Wang, R., Uljon, S. N., Sennvik, K., Näslund, J., Muehlhauser, F., Nordstedt, C., Beyreuther, K., et al. (2000) · Molecular Medicine · doi:10.1007/bf03401938 · Cited by 70
Self-citationKitazawa, M., Green, K. N., Caccamo, A., & LaFerla, F. M. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.051232 · Cited by 80
Development of a Specific Diagnostic Test for Measurement of β-Amyloid (1-42) [βA4(l-42)] in CSF
Vanderstichele, H., Blennow, K., D'Heuvaert, N., Buyse, M.-A., Wallin, A., Andreasen, N. C., Seubert, P. A., VOORDE, A. V. D., & Vanmechelen, E. (1998) · Advances in behavioral biology · doi:10.1007/978-1-4615-5337-3_110 · Cited by 76
Yu, G., Chen, F., Nishimura, M., Steiner, H., Tandon, A., Kawarai, T., Arawaka, S., Supala, A., Song, Y.-Q., Rogaeva, E., et al. (2000) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)61517-6 · Cited by 70
Proteasome inhibitors: fromin vitro uses to clinical trials
Rivett, A. J., & Gardner, R. C. (2000) · Journal of Peptide Science · doi:10.1002/1099-1387(200009)6:9<478::aid-psc285>3.0.co;2-f · Cited by 49
Evidence for lymphatic Aβ clearance in Alzheimer's transgenic mice
Pappolla, M., Sambamurti, K., Vidal, R., Pacheco-Quinto, J., Poeggeler, B., & Matsubara, E. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.07.012 · Cited by 69
Chen, C.-L., Tsai, W.-H., Chen, C.-J., & Pan, T.-M. (2016) · Journal of Traditional and Complementary Medicine · doi:10.1016/j.jtcme.2015.07.002 · Cited by 69
Leuzy, A., Ashton, N. J., Mattsson-Carlgren, N., Dodich, A., Boccardi, M., Corre, J., Drzezga, A., Nordberg, A., Ossenkoppele, R., Zetterberg, H., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05258-7 · Cited by 69
Lee, Y.-H., Martin, J. M., Maple, R. L., Tharp, W. G., & Pratley, R. E. (2009) · Neuroendocrinology · doi:10.1159/000235555 · Cited by 68
Plasma Aβ Levels Do Not Reflect Brain Aβ Levels
Freeman, S. H., Raju, S., Hyman, B. T., Frosch, M. P., & Irizarry, M. C. (2007) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31803d3ae4 · Cited by 78
The Pathogenic Aβ43 Is Enriched in Familial and Sporadic Alzheimer Disease
Sandebring, A., Welander, H., Winblad, B., Graff, C., & Tjernberg, L. O. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055847 · Cited by 69
“These mutations lead to increased production of Ab42 or to increased ratio of Ab42/Ab40 [31,32], further implicating the importance of Ab42 in AD pathogenesis.”
BackgroundIntramembrane Proteolysis of β-Amyloid Precursor Protein by γ-Secretase Is an Unusually Slow Process
Kamp, F., Winkler, E., Trambauer, J., Ebke, A., Fluhrer, R., & Steiner, H. (2015) · Biophysical Journal · doi:10.1016/j.bpj.2014.12.045 · Cited by 77
Su, G. C., Arendash, G. W., Kalaria, R. N., Bjugstad, K. B., & MULLAN, M. J. (1999) · Brain Research · doi:10.1016/s0006-8993(98)01143-3 · Cited by 71
Schmechel, A., Zentgraf, H., Scheuermann, S., Fritz, G., Pipkorn, R., Reed, J., Beyreuther, K. T., Bayer, T. A., & Multhaup, G. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303547200 · Cited by 69
Increased amyloid β protein levels in children and adolescents with Down syndrome
Mehta, P. D., Capone, G. T., Jewell, A., & Freedland, R. L. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2006.12.010 · Cited by 78
Moechars, D., Lorent, K., & Leuven, F. V. (1999) · Neuroscience · doi:10.1016/s0306-4522(98)00599-5 · Cited by 78
SNAP-25 requirement for dendritic growth of hippocampal neurons
Grosse, G., Grosse, J., Tapp, R., Kuchinke, J., Gorsleben, M., Fetter, I., Höhne-Zell, B., Gratzl, M., & Bergmann, M. (1999) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19990601)56:5<539::aid-jnr9>3.0.co;2-y · Cited by 67
Aβ deposition inhibitor screen using synthetic amyloid
Esler, W. P., Stimson, E. R., Ghilardi, J. R., Felix, A. M., Lu, Y., Vinters, H. V., Mantyh, P. W., & Maggio, J. E. (1997) · Nature Biotechnology · doi:10.1038/nbt0397-258 · Cited by 85
Quantitative analysis of co-oligomer formation by amyloid-beta peptide isoforms.
Iljina, M., Garcia, G. A., Dear, A. J., Flint, J., Narayan, P., Michaels, T. C. T., Dobson, C. M., Frenkel, D., Knowles, T. P. J., & Klenerman, D. (2016) · Scientific Reports · doi:10.1038/srep28658 · Cited by 68
Pasinetti, G. M. (2012) · Planta Medica · doi:10.1055/s-0032-1315377 · Cited by 80
Exploring the Role of PSEN Mutations in the Pathogenesis of Alzheimer’s Disease
Kabir, M. T., Uddin, M. S., Setu, J. R., Ashraf, G. M., Bin-Jumah, M. N., & Abdel‐Daim, M. M. (2020) · Neurotoxicity Research · doi:10.1007/s12640-020-00232-x · Cited by 78
Chun, Y. S., Park, Y., Oh, H. G., Kim, T.-W., Yang, H. O., Park, M. K., & Chung, S. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-140096 · Cited by 68
“C99 is further cleaved by -secretase to generate A , mostly A 40 and A 42 (amyloidogenic pathway) [3, 4].”
Ellis, K. A., Rowe, C. C., Villemagne, V. L., Martins, R. N., Masters, C. L., Salvado, O., Szoeke, C., Ames, D., & AIBL research group (2010) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.03.009 · Cited by 68
“Numerous studies have investigated Ab levels in plasma; however, a range of confounding factors have resulted in inconclusive findings [12,13].”
BackgroundFamilial clustering and genetic risk for dementia in a genetically isolated Dutch population
Sleegers, K., Roks, G., Theuns, J., Aulchenko, Y. S., Rademakers, R., Cruts, M., van Gool, W. A., Van Broeckhoven, C., Heutink, P., Oostra, B. A., et al. (2004) · Brain · doi:10.1093/brain/awh179 · Cited by 69
“…of polymorphisms that do not affect functionality (Lleo et al., 2002), we tested if these missense mutations were associated with an increased secretion of 42-residue amyloid beta protein (Ab42) proportional to 40-residue amyloid beta protein (Ab40) (Scheuner et al., 1996; Citron et al., 1997).”
BackgroundKretner, B., Trambauer, J., Fukumori, A., Mielke, J., Kuhn, P., Kremmer, E., Giese, A., Lichtenthaler, S. F., Haass, C., Arzberger, T., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505952 · Cited by 72
“…APP as well as in presenilin-1 (PS1) and its homologue presenilin-2 (PS2), which constitute the catalytic subunit of c -secretase (Lichtenthaler et al , 2011), cause an increased ratio of A b 42 to A b 40 (Scheuner et al , 1996), i.e. that FAD mutations are associated with substrate and protease.”
Kucheryavykh, L. Y., Dávila-Rodríguez, J., Rivera-Aponte, D. E., Zueva, L. V., Washington, A. V., Sanabria, P., & Inyushin, M. Y. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.11.008 · Cited by 77
Revisiting the role of brain and peripheral Aβ in the pathogenesis of Alzheimer's disease
Uddin, M. S., Kabir, M. T., Tewari, D., Mamun, A. A., Mathew, B., Aleya, L., Barreto, G. E., Bin-Jumah, M. N., Abdel‐Daim, M. M., & Ashraf, G. M. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116974 · Cited by 77
Metadata
- Authors
- Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., Larson, E., Levy-Lahad, L., Viitanen, M., Peskind, E., Poorkaj, P., Schellenberg, G., Tanzi, R., Wasco, W., Lannfelt, L., Selkoe, D., & Younkin, S.
- Affiliations
- Case Western Reserve University (US)
- Mayo Clinic (US)
- Karolinska Institutet (SE)
- Brigham and Women's Hospital (US)
- Takeda (Japan) (JP)
- University of Washington (US)
- University of South Florida (US)
- Harvard University (US)
- ORCID
- Venue
- Nature Medicine
- Published
- 1996-08
- Volume
- 2
- Issue
- 8
- Pages
- 864-870
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2101077392
- Semantic Scholar
- ce2164647cb7fb8dcec21d95359a92ec9830047a
- Cited by
- 2,599
- References
- 40
- Citations by year
- 2026: 26 · 2025: 34 · 2024: 58 · 2023: 74 · 2022: 45 · 2021: 66 · 2020: 66 · 2019: 58 · 2018: 53 · 2017: 64 · 2016: 76 · 2015: 72 · 2014: 77 · 2013: 91 · 2012: 96
- FWCI
- 102.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta, familial Alzheimer's disease, presenilin 1, presenilin 2, amyloid precursor protein, APP mutations, amyloid plaques
- MeSH terms
- Alzheimer Disease, Cells, Cultured, Female, Fibroblasts, Humans, Male, Membrane Proteins, Mutation, Peptide Fragments, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Culture Media, Conditioned, Presenilin-1, Presenilin-2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.